Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Quarterly Statistics, Q2 2009

This article was originally published in Start Up

Executive Summary

Highlights from the Q2 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $864 million--a 25% increase from Q1 2009--with most of the money, 54% or $465 million, coming out of the device industry, which saw only $127 million the previous quarter. There was one acquisition--PPD paid $14.5 million in cash for Magen BioSciences. In the most significant alliance, valued at up to $527 million, GSK got rights to three compounds from Concert Pharmaceuticals, including two in the preclinical stage, which was the most popular phase of development on Q2 alliances.

You may also be interested in...

SBI, ConforMIS Think and Act Globally in Search for Funds

Small Bone Innovations and ConforMIS drew capital from across the globe for their $144 million and $50 million financings.

Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?

Chiesi/Cornerstone: Trading Ownership for Pipeline

The Italian pharma Chiesi Farmaceutici is buying a majority stake in respiratory specialist Cornerstone Therapeutics in a creative deal that echoes the strategic tie-up last year between Infinity Pharmaceuticals and the Purdue Pharma/Mundipharma family of companies. The deal is yet another twist on the kind of big brother-little brother relationship model first espoused by Roche and Genentech though it is the little brother who gains access to pipeline projects in this new scenario.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts